Biotechnology company Cartherics, which is developing immune cell therapies for the treatment of cancer, has entered a collaborative research agreement with TiCARos Co to assess its proprietary CLIP-CAR technology in Cartherics’ induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells.
Most cybersecurity is making up for weak platforms. We need to address the fundamentals, design platforms that prevent out-of-bounds access[…]
For most developers the security/performance trade off is still the hardest one to tackle, even as the cost of processing[…]
RISC has been overhyped. While it is an interesting low-level processor architecture, what the world needs is high-level system architectures,[…]
There are two flaws that are widespread in the industry here. The first is that any platform or language should[…]
Ajai Chowdhry, one of the founders and CEO of HCL is married to a cousin of a cousin of mine.[…]